$XBI $149.21 (+4.11%) 📈
COVID:
$NVAX (+3.56%) - Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
PIPELINE:
$SRPTA (+1.50%) - Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
$ALNY (+9.91%) - Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
$MRUS (-1.16%) - Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
$GLYC (+4.32%) - APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
$ALDX (+26.42%) - Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
$BTNX (+2.78%) - BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
$AQST (+3.25%) - Aquestive Therapeutics Provides Business Update
$DVAX (+6.52%) - Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
$KALA (+3.96%) - Kala Pharmaceuticals Announces Availability of EYSUVISâ„¢ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline
$LOGC (+1.85%) - LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute
$PRAX (+4.62%) - Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs
FINANCIAL:
$CERC (+2.11%) - Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
$ARCT (+35.65%) - Wells Fargo Initiates Coverage On Arcturus Therapeutics with Overweight Rating
$AMRN (+9.69%) - Amarin Provides Preliminary 2020 Results and 2021 Outlook
$EIGR (-8.06%) - Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans https://ir.eigerbio.com/news-releases/news-release-details/eiger-biopharmaceuticals-updates-2020-progress-and-2021-plans
$RVNC (+8.79%) - Revance Provides Corporate Update and Anticipated Milestones for 2021 https://investors.revance.com/news-releases/news-release-details/revance-provides-corporate-update-and-anticipated-milestones-0
Commentaires